| Zacks Company Profile for Myrexis Inc. (MYRX : OTC) |
|
|
| |
| • Company Description |
| Myrexis, Inc., formerly known as Myriad Pharmaceuticals, Inc., is a biotechnology company focused on discovering, developing, and commercializing novel therapies for the treatment of cancer. The Company's product pipeline includes Azixa (verubulin, MPC-6827), a microtubule destabilizer for brain cancer; MPC-3100, an HSP90 inhibitor for cancer; MPC-9528, a Cancer Metabolism Inhibitor; MPI-485520, an IKK inhibitor for cancer and inflammation; and others. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 51,531 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 0.63 |
| 52 Week High: $0.01 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-60.00% |
-61.47% |
| 12 Week |
-97.14% |
-97.70% |
| Year To Date |
-97.14% |
-97.29% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Jonathan M. Couchman - Chairman of the Board
Steven D. Scheiwe - Director
Michael C. Pearce - Director
John T. Henderson, M.D. - Director
Dennis H. Langer, M.D., J.D. - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 62856H107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 0.63
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
